Close

Anti-NY-ESO-1 scFv h(41BB-CD3ζ) CART, pCDCAR1 (CAR-T-2-M323-BZ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-NY-ESO-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human NY-ESO-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-NY-ESO-1 antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of metastatic melanoma and synovial cell sarcoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • NY-ESO-1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Metastatic melanoma; synovial cell sarcoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • ES121
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • cancer/testis antigen 1B
  • Synonyms
  • CTAG; ESO1; CT6.1; CTAG1; LAGE-2; LAGE2B; NY-ESO-1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data ELISA

Fig.1 Antibody titration of positive clone mAb 2D2 via ELISA.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.1 Antibody titration of positive clone mAb 2D2 via ELISA.

Selection of scFvs specific for HLA-A2/NY-ESO-1 complex.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

Complete CAR data BLI

Fig.2 Binding affinity of mAb 2D2 to the HLA-A2/NY-ESO-1157-165.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.2 Binding affinity of mAb 2D2 to the HLA-A2/NY-ESO-1157-165.

The complex measured by the biolayer interferometry (BLI) on an Octet instrument.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

Complete CAR data FCM

Fig.3 Surface expression of CAR detected by HLA-A2/NY-ESO-1157-165 complex.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.3 Surface expression of CAR detected by HLA-A2/NY-ESO-1157-165 complex.

2D2-CAR T cells specifically recognize and lyze HLA-A2+/NY-ESO-1+cells in vitro.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

Complete CAR data Cyt

Fig.4 LDH cytotoxicity assay of 2D2-CAR T cells.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.4 LDH cytotoxicity assay of 2D2-CAR T cells.

2D2-CAR T cells were cocultured with T2 cells that were pulsed with 20µg/mL NY-ESO-1 or CMV peptide for 1 hour for 4 hours.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

Complete CAR data FuncS

Fig.5 2D2-CAR T cells impair tumor growth and prolong the survival of mice bearing triple-negative breast cancer in vivo.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.5 2D2-CAR T cells impair tumor growth and prolong the survival of mice bearing triple-negative breast cancer in vivo.

Representative survival analysis of MBA-MD-231-NY-ESO-1 bearing mice treated with 2D2-CAR T cells compared with the control group.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

Complete CAR data ELISA

Fig.6 IFN-γcytokine release measured by ELISA.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.6 IFN-γcytokine release measured by ELISA.

2D2-CAR T cells were cocultured with target cells with a 10:1 (E: T) ratio overnight.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

Complete CAR data IHC

Fig.7 Confocal imaging of mAb 2D2 staining in NY-ESO1157-165 peptide-pulsed HEK 293T.

CAR Construction : 2D2 scFv-BBζ Latest CAR Construction

Fig.7 Confocal imaging of mAb 2D2 staining in NY-ESO1157-165 peptide-pulsed HEK 293T.

HEK 293T cells were pulsed with 20µg/mL NY-ESO-1157-165 or CMV pp65495-503 peptide for 1 hour.

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., ... & Wang, R. (2022). Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for immunotherapy of cancer, 10(3).

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-NY-ESO-1 scFv h(41BB-CD3ζ) CART, pCDCAR1 (CAR-T-2-M323-BZ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.